###begin article-title 0
###xml 58 67 58 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9</italic>
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXB5</italic>
###xml 99 106 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1</italic>
###xml 112 119 112 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1 </italic>
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 203 212 203 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
The epigenetics of ovarian carcinogenesis remains poorly described. We have in the present study investigated the promoter methylation status of 13 genes in primary ovarian carcinomas (n = 52) and their in vitro models (n = 4; ES-2, OV-90, OVCAR-3, and SKOV-3) by methylation-specific polymerase chain reaction (MSP). Direct bisulphite sequencing analysis was used to confirm the methylation status of individual genes. The MSP results were compared with clinico- pathological features.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 176 181 176 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9</italic>
###xml 183 190 183 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 192 195 192 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 197 202 197 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH13</italic>
###xml 204 209 204 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXB5</italic>
###xml 211 226 211 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1 (HIN-1)</italic>
###xml 228 234 228 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1</italic>
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 400 407 400 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADAMTS1</italic>
###xml 409 413 409 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGMT</italic>
###xml 415 420 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR3C1</italic>
###xml 422 425 422 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p14</italic>
###xml 425 428 425 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARF</italic>
###xml 425 428 425 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ARF</italic></sup>
###xml 434 437 434 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 437 440 437 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK</italic>
###xml 441 443 441 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 437 443 437 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK</italic>4<italic>a </italic></sup>
###xml 508 514 508 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 518 526 518 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1 </italic>
###xml 642 644 642 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 653 655 653 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 772 778 772 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 911 913 911 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 970 976 970 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 1028 1030 1028 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 827 835 <span type="species:ncbi:9606">patients</span>
Eight out of the 13 genes were hypermethylated among the ovarian carcinomas, and altogether 40 of 52 tumours were methylated in one or more genes. Promoter hypermethylation of HOXA9, RASSF1A, APC, CDH13, HOXB5, SCGB3A1 (HIN-1), CRABP1, and MLH1 was found in 51% (26/51), 49% (23/47), 24% (12/51), 20% (10/51), 12% (6/52), 10% (5/52), 4% (2/48), and 2% (1/51) of the carcinomas, respectively, whereas ADAMTS1, MGMT, NR3C1, p14ARF, and p16INK4a were unmethylated in all samples. The methylation frequencies of HOXA9 and SCGB3A1 were higher among relatively early-stage carcinomas (FIGO I-II) than among carcinomas of later stages (FIGO III-IV; P = 0.002, P = 0.020, respectively). The majority of the early-stage carcinomas were of the endometrioid histotype. Additionally, HOXA9 hypermethylation was more common in tumours from patients older than 60 years of age (15/21) than among those of younger age (11/30; P = 0.023). Finally, there was a significant difference in HOXA9 methylation frequency among the histological types (P = 0.007).
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9</italic>
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXB5</italic>
###xml 124 131 124 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1</italic>
###xml 137 144 137 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1 </italic>
DNA hypermethylation of tumour suppressor genes seems to play an important role in ovarian carcinogenesis and HOXA9, HOXB5, SCGB3A1, and CRABP1 are identified as novel hypermethylated target genes in this tumour type.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 286 287 286 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 329 330 329 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 544 552 <span type="species:ncbi:9606">patients</span>
Ovarian cancer is often not detected until it has reached an advanced stage and is therefore among the most lethal gynaecological cancer diseases. Tumour stage at diagnosis, residual disease following cytoreductive surgery, and performance status which is evaluated by Karnofsky Index [1] are the three major prognostic factors [2]. Epithelial ovarian carcinoma accounts for over 90% of all cases and includes the following major histological subtypes: serous-, mucinous-, endometrioid-, and clear cell- carcinomas. In Norway, more than 90% of patients with ovarian carcinoma are older than 40 years, with a peak incidence at the age of 75-79 [3].
###end p 9
###begin p 10
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 438 439 438 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 651 652 651 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1127 1134 1127 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGFBP-3</italic>
###xml 1137 1138 1137 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1186 1191 1186 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DLEC1</italic>
###xml 1194 1195 1194 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1225 1231 1225 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1232 1234 1232 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 681 686 <span type="species:ncbi:9606">human</span>
A number of genetic changes have been shown to accumulate during carcinogenesis, including DNA copy number changes and various types of gene mutations. Simultaneously, several epigenetic changes have been shown to be present and possibly participate in the carcinogenesis [4,5]. DNA methylation is a well-studied epigenetic mechanism, defined as a heritable and enzyme-induced chemical modification of DNA, not altering the DNA sequence [6]. In higher order eukaryotes, cytosines located 5' to guanosines in so-called CpG sites are the targets for methylation and a high density of such sites within a limited stretch of DNA constitutes a CpG island [7]. Approximately half of the human genes contain such CpG islands in their 5' regulatory sequence, and DNA hypermethylation of this region is associated with lost or reduced gene expression, representing an important alternative mechanism for the inactivation of tumour suppressor- and DNA repair- genes. Among ovarian carcinomas, only a handful such genes have been shown to exhibit DNA promoter hypermethylation, including the Insulin-like growth factor binding protein-3 (IGFBP-3) [8], the Deleted in Lung and Esophageal Cancer 1 (DLEC1) [9], and the breast cancer gene BRCA1 [10].
###end p 10
###begin p 11
###xml 42 45 42 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 45 48 45 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK</italic>
###xml 49 51 49 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 45 51 45 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK</italic>4<italic>a </italic></sup>
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A</italic>
###xml 83 85 83 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK </italic>
###xml 267 273 267 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 803 806 803 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 808 813 808 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH13</italic>
###xml 815 819 815 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGMT</italic>
###xml 821 825 821 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1</italic>
###xml 827 830 827 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p14</italic>
###xml 830 833 830 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARF</italic>
###xml 830 833 830 833 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ARF</italic></sup>
###xml 835 838 835 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 838 841 838 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK</italic>
###xml 842 843 842 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 838 843 838 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK</italic>4<italic>a</italic></sup>
###xml 845 852 845 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 909 916 909 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADAMTS1</italic>
###xml 918 924 918 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1</italic>
###xml 926 931 926 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9</italic>
###xml 933 938 933 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXB5</italic>
###xml 940 945 940 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR3C1</italic>
###xml 947 954 947 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1</italic>
Some genes, like the cell cycle inhibitor p16INK4a (CDKN2A) and estrogen receptor (ER), are frequently hypermethylated across several cancer types, whereas others are more common in specific cancer types, such as hypermethylated DAPK in lung cancer and lymphoma, and GSTP1 in prostate-, breast-, kidney-, and liver cancer [11]. Hence, hypermethylation of target genes seems to be tumour-type specific and can potentially be used in the clinic to detect neoplasms, predict tumour response, and develop therapies that target hypermethylated tumour suppressor genes [12,13]. Here, we present the DNA methylation profile of 13 genes in a series of ovarian carcinomas and cancer cell lines. The investigated gene promoters were chosen from loci previously reported to be methylated in ovarian cancer (n = 7; APC, CDH13, MGMT, MLH1, p14ARF, p16INK4a, RASSF1A) and from loci methylated in other tumour types (n = 6; ADAMTS1, CRABP1, HOXA9, HOXB5, NR3C1, SCGB3A1).
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Gene promoter methylation in ovarian carcinomas
###end title 13
###begin p 14
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 350 351 350 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 413 419 413 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 423 431 423 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 513 517 513 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 521 527 521 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH13 </italic>
###xml 604 609 604 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXB5</italic>
###xml 611 618 611 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1</italic>
###xml 620 627 620 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1 </italic>
###xml 631 636 631 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 757 764 757 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADAMTS1</italic>
###xml 766 770 766 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGMT</italic>
###xml 772 777 772 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR3C1</italic>
###xml 779 782 779 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p14</italic>
###xml 782 785 782 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARF</italic>
###xml 782 785 782 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ARF</italic></sup>
###xml 790 793 790 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 793 796 793 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK</italic>
###xml 797 798 797 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 793 798 793 798 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK</italic>4<italic>a</italic></sup>
Eight out of the 13 genes analyzed by methylation-specific polymerase chain reaction (MSP) showed promoter hypermethylation in one or more of the primary ovarian carcinomas (n = 52), and altogether 77% (40/52) of these tumours harboured promoter hypermethylation in at least one of these eight genes. The results are summarized in Table 1 and Figure 1, and representative MSP gel bands are presented in Figure 2. HOXA9 and RASSF1A were hypermethylated in high frequencies (26/51 51% and 23/47 49%, respectively), APC and CDH13 at intermediate frequencies (12/51 24% and 10/51 20%, respectively), whereas HOXB5, SCGB3A1, CRABP1 and MLH1 were less frequently methylated (6/52 12%, 5/52 10%, 2/48 4%, and 1/51 2%, respectively). No methylation was detected in ADAMTS1, MGMT, NR3C1, p14ARF, or p16INK4a. Furthermore, benign (n = 2) and borderline (n = 2) ovarian tumours were unmethylated for all analyzed genes.
###end p 14
###begin p 15
Methylation correlated with clinical features in ovarian carcinomas
###end p 15
###begin p 16
###xml 36 38 36 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 105 107 105 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
Abbreviations: NS, no significance; P values are two-sided and considered statistically significant when P <= 0.05. The table is based on 52 primary carcinomas from 50 patients.
###end p 16
###begin p 17
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Methylation profile of primary ovarian carcinomas</bold>
###xml 162 169 162 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADAMTS1</italic>
###xml 171 175 171 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGMT</italic>
###xml 177 187 177 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR3C1, p14</italic>
###xml 187 190 187 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARF</italic>
###xml 187 190 187 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ARF</italic></sup>
###xml 196 199 196 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 199 202 199 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK</italic>
###xml 203 205 203 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 199 205 199 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK</italic>4<italic>a </italic></sup>
Methylation profile of primary ovarian carcinomas. Thirteen genes were analyzed by methylation-specific polymerase chain reaction (MSP) in 52 ovarian carcinomas. ADAMTS1, MGMT, NR3C1, p14ARF, and p16INK4a were unmethylated in all tumours samples analyzed and are excluded from the figure. Axis Y represents the promoter methylation percentage of individual genes.
###end p 17
###begin p 18
###xml 0 107 0 107 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Representative methylation-specific polymerase chain reaction (MSP) results from primary ovarian carcinomas</bold>
###xml 275 281 275 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 387 394 387 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1</italic>
###xml 504 513 504 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Representative methylation-specific polymerase chain reaction (MSP) results from primary ovarian carcinomas. PCR products in lane U indicate the presence of unmethylated alleles whereas PCR products in lanes M indicate the presence of methylated alleles. Panel A illustrates HOXA9 (the upper bands represent MSP products, whereas the lower bands are excess primers). Panel B illustrates SCGB3A1. Abbreviation: Pos, positive control (DNA from normal blood is used as control for unmethylated samples, and in vitro methylated DNA is used as control for methylated samples); Neg, negative control (template replaced by water); Lane 1-6, individual ovarian carcinomas; 100 bp DNA marker from Promega Corp, Madison, WI, USA. The illustration has been processed from a photo including more samples. Hence, the controls have been moved from their original position and pasted adjacent to the selected samples shown here.
###end p 18
###begin title 19
Gene promoter methylation in ovarian cancer cell lines
###end title 19
###begin p 20
###xml 69 70 69 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 72 75 72 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH13</italic>
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1</italic>
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9</italic>
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXB5</italic>
###xml 106 113 106 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 119 127 119 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1 </italic>
###xml 230 238 230 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADAMTS1 </italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGMT </italic>
###xml 300 304 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1</italic>
###xml 306 311 306 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR3C1</italic>
###xml 313 316 313 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p14</italic>
###xml 316 319 316 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARF</italic>
###xml 316 319 316 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ARF</italic></sup>
###xml 325 328 325 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 328 331 328 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK</italic>
###xml 332 334 332 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 328 334 328 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK</italic>4<italic>a </italic></sup>
The detailed methylation status for each cell line is shown in Table 2. APC, CDH13, CRABP1, HOXA9, HOXB5, RASSF1A, and SCGB3A1 were found to be hypermethylated both in the primary tumours and in ovarian cancer cell lines, whereas ADAMTS1 and MGMT were hypermethylated only among cell lines. Finally, MLH1, NR3C1, p14ARF, and p16INK4a were unmethylated in all cell lines.
###end p 20
###begin p 21
Methylation status in ovarian cancer cell lines
###end p 21
###begin p 22
Abbreviation: U, unmethylated; M: methylated.
###end p 22
###begin title 23
Verification of DNA promoter methylation by bisulphite sequencing
###end title 23
###begin p 24
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH13</italic>
###xml 7 13 7 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1</italic>
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9</italic>
###xml 26 34 26 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1 </italic>
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 382 383 382 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
CDH13, CRABP1, HOXA9, and SCGB3A1 were subjected to direct bisulphite sequencing in the four ovarian carcinoma cell lines. In general, there was a good concordance between MSP status and bisulphite sequences, limiting the potential detection of false positives by the first method. The results are summarized in Figure 3 and representative electropherograms are displayed in Figure 4.
###end p 24
###begin p 25
###xml 0 124 0 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Direct bisulphite sequencing verified methylation status as assessed by methylation-specific polymerase chain reaction (MSP)</bold>
###xml 172 194 172 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 (a), SCGB3A1 (b)</italic>
###xml 200 210 200 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1 (c)</italic>
Direct bisulphite sequencing verified methylation status as assessed by methylation-specific polymerase chain reaction (MSP). Methylation status of individual CpG sites in HOXA9 (a), SCGB3A1 (b), and CRABP1 (c). The upper panel of each gene shows the CpG sites (vertical bars) amplified by the bisulphite sequencing primers. Bent arrows indicate the location of the MSP primers, whereas straight arrows indicate the transcription start site of individual genes. Black filled circles represent methylated CpGs; Open circles represent unmethylated CpGs; Gray circles represent partial methylation, defined as 21-80% methylation. The column at the right side of each panel (U, M, and U/M) shows the methylation status as assessed by MSP analysis.
###end p 25
###begin p 26
###xml 0 37 0 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Bisulphite sequence electropherograms</bold>
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 241 248 241 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1 </italic>
Bisulphite sequence electropherograms. Panel a) illustrates CpG sites 9-14 from the HOXA9 bisulphite sequencing fragment in the methylated ES-2 cell line (top) and unmethylated control (bottom). Panel b) illustrates CpG sites 15-19 from the CRABP1 bisulphite sequencing fragment also from the methylated ES-2 cell line and unmethylated control. CpG sites are indicated by arrows, whereas originally Cs converted to Ts by bisulphite sequencing are underlined. For both genes, bisulphite treated normal blood was used as unmethylated control.
###end p 26
###begin title 27
Methylation profile compared with clinical characteristics
###end title 27
###begin p 28
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9</italic>
###xml 297 299 297 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 314 315 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
Patients over and under 60 years of age (mean across all patients = 58 years) displayed a similar distribution regarding FIGO stage, histology, and promoter methylation frequencies, with the exception of hypermethylated HOXA9, which was significantly more frequent in tumours from older patients (P = 0.023; Table 1).
###end p 28
###begin p 29
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXB5</italic>
###xml 458 464 458 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 468 476 468 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1 </italic>
###xml 477 479 477 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 488 490 488 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 552 556 552 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 557 559 557 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 344 352 <span type="species:ncbi:9606">patients</span>
By comparing the distribution of histological type and clinical stage, we found that 14 out of 17 carcinomas of the endometrioid type were of FIGO stages I to II and 18 out of 19 carcinomas of the serous histotype were of FIGO stages III to IV. With the exception of HOXB5, higher promoter methylation frequencies were found among tumours from patients with relatively early FIGO stages (I-II) than late stages, but reached statistical significance only for HOXA9 and SCGB3A1 (P = 0.002, P = 0.020, respectively). The same trend could also be seen for APC (P = 0.052).
###end p 29
###begin p 30
###xml 154 156 154 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH13</italic>
###xml 245 251 245 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1</italic>
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 264 266 264 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 275 277 275 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 286 288 286 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 341 349 341 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1 </italic>
###xml 416 418 416 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Across all genes analyzed, the serous subtype displayed the lowest frequencies of hypermethylation, whereas the clear cell tumours displayed the highest (P = 0.078, Kruskal-Wallis test). At the single gene level, this was significant for CDH13, CRABP1, and HOXA9 (P = 0.041, P < 0.001, P = 0.007, respectively). Further, the promoter of the SCGB3A1 gene was only hypermethylated among mucous and clear cell tumours (P < 0.001).
###end p 30
###begin p 31
No association could be seen between methylation frequency and grade of tumour differentiation.
###end p 31
###begin p 32
Finally, four ovarian carcinomas showed simultaneous methylation of four or more out of the 13 genes analyzed. Three of these tumours were of the clear cell histotype, whereas the last tumour was endometrioid. The remaining carcinomas displayed in average 1.4 methylated genes.
###end p 32
###begin title 33
Methylation profiles compared with microsatellite instability (MSI)
###end title 33
###begin p 34
###xml 319 321 319 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 583 589 583 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXB5 </italic>
###xml 615 617 615 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
In this study, microsatellite instability (MSI) status was analyzed in 54 samples including 50 carcinomas, 2 borderline, and 2 benign tumours. MSI was seen in a single carcinoma of mixed histotype. Further, seven ovarian carcinomas were MSI-low, significantly associated with the clear cell and endometrioid histotype (P = 0.013). The remaining samples (n = 46) were microsatellite stable (MSS). MSI status was not associated with any additional clinical parameters, such as FIGO stage, differentiation grade or age, although MSI-low carcinomas had a higher methylation frequency of HOXB5 than did the MSS tumours (P = 0.006).
###end p 34
###begin p 35
Among the four ovarian cancer cell lines, SKOV-3 was MSI whereas the other cell lines displayed a MSS phenotype.
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 137 142 137 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9</italic>
###xml 144 149 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXB5</italic>
###xml 151 158 151 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1</italic>
###xml 164 170 164 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1</italic>
Our data support the view that promoter hypermethylation is a common mechanism involved in ovarian carcinogenesis and four target genes, HOXA9, HOXB5, SCGB3A1, and CRABP1, novel to this cancer type are identified.
###end p 37
###begin p 38
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 206 212 206 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXB5 </italic>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 338 344 338 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 470 476 470 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 658 664 658 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 1128 1134 1128 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 1219 1225 1219 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 1449 1455 1449 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 1456 1458 1456 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1552 1558 1552 1558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 1805 1807 1805 1807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1808 1810 1808 1810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1928 1934 1928 1934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 187 192 <span type="species:ncbi:10090">mouse</span>
###xml 1388 1392 <span type="species:ncbi:10090">mice</span>
###xml 1619 1627 <span type="species:ncbi:9606">patients</span>
###xml 1657 1665 <span type="species:ncbi:9606">patients</span>
Homeodomain-containing (HOX) genes encode transcriptional factors functioning during embryonic development to control patterning, differentiation, and proliferation (see review [14]). In mouse development, HOXB5 shows tissue specific methylation in the adult, but is unmethylated in the fetal tissues [15]. High methylation percentage of HOXA9 has been reported in early stages of primary squamous cell carcinomas of the lung [16]. In the present study, the promoter of HOXA9 was frequently hypermethylated and associated with early-stage (FIGO stage I-II) ovarian carcinomas. Interestingly, the majority of these tumours were of the endometrioid histotype. HOXA9 hypermethylation was also present in the other histological subtypes, including the serous type, which across all analyzed genes displayed the lowest frequency of promoter methylation. No normal ovarian samples were included in the present study. The proper normal control would be the epithelial lining of the ovaries, which consists of a single cell layer. However, the lack of methylation in benign and borderline tumours as well as in blood indicates that the HOXA9 promoter is unmethylated in the normal situation. Hence, aberrant gene expression of HOXA9 may be involved in the molecular pathway of ovarian carcinogenesis. A previous study has suggested that the development of various histotypes of ovarian cancer in mice is partly dependent on the ectopic expression levels of HOXA9 [17], however, additional studies are needed before this can be concluded. In the present study, HOXA9 promoter methylation was more frequent in tumours from older patients than in tumours from younger patients. Aging is one the most important risk factors for development of neoplasia and methylation has previously been shown to increase with age [18,19]. The peak incidence of ovarian cancer is over 60 years, and aging can therefore not be excluded as a contributor to HOXA9 hypermethylation in this disease.
###end p 38
###begin p 39
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1</italic>
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HIN1 </italic>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 553 561 553 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1 </italic>
SCGB3A1, also named HIN1 (high in normal-1), encodes a small secreted protein, secretoglobin 3A1, and belongs to the secretoglobin family [20]. It is reported to be a potent inhibitor of anchorage-dependent and anchorage-independent cell growth, cell migration, and invasion [21]. Hypermethylation-induced down-regulation of this gene has been found in several cancer types, such as breast-, non-small cell lung-, small cell lung-, colorectal-, and testicular- cancer, suggesting a potential tumour suppressor function [22,23]. We demonstrate here that SCGB3A1 promoter hypermethylation also occurs in ovarian carcinomas, suggesting that this event plays a role in the development of a subgroup of these tumours.
###end p 39
###begin p 40
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADAMTS1</italic>
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1</italic>
###xml 75 81 75 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR3C1 </italic>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 450 456 450 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1</italic>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 684 691 684 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADAMTS1</italic>
###xml 733 735 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 852 858 852 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR3C1 </italic>
###xml 1020 1022 1020 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1053 1060 1053 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADAMTS1</italic>
###xml 1062 1068 1062 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1</italic>
###xml 1074 1080 1074 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR3C1 </italic>
Recently, we showed that promoter hypermethylation of ADAMTS1, CRABP1, and NR3C1 was frequent among colorectal carcinomas and cell lines and to a certain extent in colorectal adenomas [24]. Since ovarian cancer also belongs to the hereditary non-polyposis colorectal cancer (HNPCC) tumour spectrum and the fact that sporadic tumours of the same type often exhibit the same molecular aberrations, these three genes were included in the present study. CRABP1, which is a member of a family of small cytosolic lipid binding proteins and encodes a cellular retinoic acid binding protein [25], was the only gene in which hypermethylation was found and then only in two clear cell tumours. ADAMTS1, a metalloproteinase of the ADAM family [26], was found methylated in a single OV-90 cell line but not in ovarian carcinomas. The CpG island in the promoter of NR3C1 remained unmethylated in all the samples. These findings, and the fact that neither prostate-, kidney-, nor testicular- cancer showed methylation of these genes [24], support the hypothesis that ADAMTS1, CRABP1, and NR3C1 are targeted by hypermethylation preferentially in colorectal tumours.
###end p 40
###begin p 41
###xml 125 128 125 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH13</italic>
###xml 137 141 137 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGMT</italic>
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1</italic>
###xml 149 152 149 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p14</italic>
###xml 152 155 152 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARF</italic>
###xml 152 155 152 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ARF</italic></sup>
###xml 157 160 157 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 160 163 160 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK</italic>
###xml 164 165 164 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 160 165 160 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK</italic>4<italic>a</italic></sup>
###xml 171 178 171 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 184 192 184 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 201 205 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 218 224 218 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH13 </italic>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 459 462 459 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 462 465 462 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK</italic>
###xml 466 468 466 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 462 468 462 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK</italic>4<italic>a </italic></sup>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 720 723 720 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p14</italic>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARF </italic>
###xml 723 727 723 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ARF </italic></sup>
###xml 731 734 731 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 734 737 734 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK</italic>
###xml 738 740 738 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 734 740 734 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK</italic>4<italic>a </italic></sup>
###xml 830 832 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 857 862 857 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 865 867 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 900 903 900 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 903 906 903 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK</italic>
###xml 907 909 907 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 903 909 903 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK</italic>4<italic>a </italic></sup>
Additionally, we analyzed seven genes which have previously been reported to be hypermethylated in ovarian cancer, including APC, CDH13, MGMT, MLH1, p14ARF, p16INK4a, and RASSF1A. For RASSF1A [27,28], APC [29,30], and CDH13 [31], we found comparable methylation frequencies to previous reports, which have also shown that promoter hypermethylation of these genes are associated with loss of gene expression in various tumour types [31-33]. The methylation of p16INK4a has been shown to be important in tumour development in several tissue types, such as the colon, lung, head and neck, pancreas, cervix, large bowel, leukemia and lymphoma but is seemingly not important in ovarian cancer [34-36]. Here we find that both p14ARF and p16INK4a were unmethylated in all samples analyzed, which is in agreement with most other reports [35,37]. However, McCluskey et al. [38] identified a high frequency of p16INK4a methylation in ovarian tumours of low malignant potential, compared with malignant carcinomas.
###end p 41
###begin p 42
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 203 208 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 427 431 427 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1</italic>
###xml 473 478 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 625 629 625 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGMT</italic>
###xml 824 829 824 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1 </italic>
###xml 833 838 833 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGMT </italic>
###xml 731 736 <span type="species:ncbi:9606">human</span>
Approximately, seventy percent of the microsatellite unstable sporadic colorectal carcinomas results from loss of MLH1 caused by DNA promoter hypermethylation [39]. In ovarian carcinomas, methylation of MLH1 is less common and has been reported only among clear cell and endometrioid subtypes [40]. In the present study, only one ovarian carcinoma, belonging to the endometrioid subtype, harboured promoter hypermethylation of MLH1. The methylation did not lead to loss of MLH1 expression since no sign of a MSI phenotype was shown in this tumour, indicating that at least one allele is likely to stay unaffected. Similarly, MGMT, a second repair enzyme encoding gene, was methylated in a single cell line ES-2, established from a human primary clear cell carcinoma, but not in any clinical samples. Although methylation of MLH1 and MGMT was uncommon in the present study, we cannot rule out that epigenetic inactivation of DNA repair genes may be a mechanism associated with specific subtypes of ovarian cancer.
###end p 42
###begin p 43
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
In colorectal tumours, a CpG island methylator phenotype (CIMP) has been suggested, characterized by frequent promoter hypermethylation [41] and associated with the MSI phenotype [42]. The concept of CIMP has also been demonstrated in other cancer types, such as gastric cancer [43]. From the present findings, CIMP does not seem to be common among ovarian carcinomas, as only few tumours showed simultaneous hypermethylation of several genes. However, CIMP is not merely defined by the methylation frequency of randomly selected genes, but rather by assessing the methylation status of a specific gene panel [44]. Hence, further studies including more MSI positive samples are required to shed light on CIMP in ovarian carcinomas. The frequently methylated ovarian carcinomas identified here belonged to the clear cell- and endometrioid histotype, suggesting that wide-spread methylation may be associated with distinct subgroups of ovarian tumours.
###end p 43
###begin p 44
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 808 810 808 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 811 813 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 878 884 878 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9 </italic>
###xml 888 896 888 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 1126 1130 1126 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1134 1142 1134 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1 </italic>
###xml 1420 1425 1420 1425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 1428 1430 1428 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 192 197 <span type="species:ncbi:9606">women</span>
###xml 485 493 <span type="species:ncbi:9606">patients</span>
###xml 554 562 <span type="species:ncbi:9606">patients</span>
###xml 798 806 <span type="species:ncbi:9606">patients</span>
###xml 917 924 <span type="species:ncbi:9606">patient</span>
###xml 1007 1015 <span type="species:ncbi:9606">patients</span>
The five-year survival rate for patients with early stage ovarian cancer (FIGO stage I-II) and advanced stage cancer (FIGO stage III-IV) is 72% and 27%, respectively [45]. Unfortunately, most women receive their diagnosis at a late stage when the chance of cure is low [46], which might in part be explained by the non-specific nature of the symptoms [47]. Identification of biomarkers for early detection of disease could therefore significantly improve the survival rate among these patients. Methylated DNA can be detected in various body fluids from patients with neoplasia and the methylation status of individual as well as panels of genes can potentially be used for risk assessment [48]. DNA methylation has previously been identified in both serum and peritoneal fluid from ovarian cancer patients [49,50]. In the present study, we find high methylation frequencies of HOXA9 and RASSF1A in tumours from this patient group. If the promoter methylation can be detected also in body fluids from these patients, the genes represent epigenetic markers that might be included in a non-invasive diagnostic test. Even though APC and SCGB3A1 promoter methylation is less frequent, it is nevertheless associated with early stage ovarian tumours and might also have a diagnostic potential. An association between high promoter methylation frequencies and early stage ovarian carcinomas has recently also been shown by Tam et al. [51].
###end p 44
###begin title 45
Conclusion
###end title 45
###begin p 46
###xml 132 144 132 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9, HOXB5</italic>
###xml 146 153 146 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1</italic>
###xml 159 165 159 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1</italic>
CpG island promoter hypermethylation of tumour suppressor genes is a common event in primary ovarian carcinomas and cell lines, and HOXA9, HOXB5, SCGB3A1, and CRABP1, represent novel hypermethylated target genes in this disease.
###end p 46
###begin title 47
Methods
###end title 47
###begin title 48
Tissue samples
###end title 48
###begin p 49
###xml 490 491 490 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Fifty-six fresh frozen ovarian tissue samples, surgically removed between 1993 and 2005, were collected from a tissue bank at Department of Pathology, Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo. Fifty-two were carcinomas, including nineteen tumours of the serous histotype, five of mucous, five of clear cell, seventeen of endometrioid, and six of mixed histotype. In addition, two benign and two borderline ovarian tumours were included in the present study (Table 1). The study has been approved by The Regional Committee for Medical Research Ethics South of Norway (S-06277a), The Social and Health Directorate (06/3280), and The Data Inspectorate (06/5345).
###end p 49
###begin title 50
Ovarian carcinoma cell lines
###end title 50
###begin p 51
###xml 359 367 <span type="species:ncbi:9606">patients</span>
###xml 448 454 <span type="species:ncbi:9913">bovine</span>
Four ovarian carcinoma cell lines, ES-2, OV-90, OVCAR-3, and SKOV-3 (American Type Culture Collection, Manassas, USA) were included in the present study. The ES-2 cell line has originally been derived from a poorly differentiated ovarian clear cell carcinoma with fibroblast morphology. The remaining cell lines have been cultured from malignant ascites from patients with adenocarcinoma. All cell lines were cultured in RPMI medium with 10% fetal bovine serum, 2 mM L-Glutamine, 100 units/ml penicillin, and 100 ug/ml streptomycin. All reagents are from Cambrex Bio Science Verviers in Belgium.
###end p 51
###begin title 52
DNA extraction
###end title 52
###begin p 53
Genomic DNA from fresh frozen ovarian cancer specimens and ovarian carcinoma cell lines was extracted using the 340A Nucleic Acid Extractor (Applied Biosystems, Foster City, CA, USA), applying standard phenol/chloroform extraction followed by ethanol precipitation.
###end p 53
###begin title 54
Bisulphite modification of DNA and methylation-specific polymerase chain reaction (MSP)
###end title 54
###begin p 55
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1020 1022 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1043 1050 1009 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADAMTS1</italic>
###xml 1052 1055 1018 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 1057 1062 1023 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH13</italic>
###xml 1064 1070 1030 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CRABP1</italic>
###xml 1072 1077 1038 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA9</italic>
###xml 1079 1084 1045 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXB5</italic>
###xml 1086 1090 1052 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGMT</italic>
###xml 1092 1096 1058 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1</italic>
###xml 1098 1103 1064 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NR3C1</italic>
###xml 1105 1108 1071 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p14</italic>
###xml 1108 1111 1074 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARF</italic>
###xml 1108 1111 1074 1077 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ARF</italic></sup>
###xml 1113 1116 1079 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p16</italic>
###xml 1116 1119 1082 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK</italic>
###xml 1120 1121 1086 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1116 1121 1082 1087 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK</italic>4<italic>a</italic></sup>
###xml 1123 1130 1089 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 1136 1143 1102 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1</italic>
###xml 1370 1372 1336 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1439 1440 1404 1405 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1734 1743 1698 1707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1748 1753 1712 1717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SssI </italic>
###xml 1666 1671 <span type="species:ncbi:9606">Human</span>
DNA from all samples was treated with sodium bisulphite, which converts all unmethylated cytosines to uracils, whereas methylated cytosines remain unchanged [52]. Briefly, 1.3 mug of DNA was denatured by incubation with 0.3 M NaOH for 15 min at 37degreesC. Hydroquinone (Sigma Chemical Co., St. Louis, MO, USA) and sodium bisulphite (Sigma Chemical Co, USA) at pH 5.0 were added to the samples to a final concentration of one mM and 3.7 M, respectively, prior to incubation at 50degreesC for 16 h. Bisulphite treated DNA was purified using the Wizard DNA clean-up kit (Promega Corp, Madison, WI, USA) and eluted in 100 muL MQ water. In order to complete the conversion of unmethylated cytosines, NaOH was added to a final concentration of 0.3 M and the samples were incubated for 15 minutes at 37degreesC. Modified DNA was precipitated with 100% ethanol, 10 mug glycogen, and 0.3 M AcNH4 at minus 80degreesC overnight, then re-suspended in 30 mul MQ water, and stored at 4degreesC. Thirteen genes were subjected to MSP [53], more specifically ADAMTS1, APC, CDH13, CRABP1, HOXA9, HOXB5, MGMT, MLH1, NR3C1, p14ARF, p16INK4a, RASSF1A, and SCGB3A1. Since bisulphite modification leads to sequence differences, two pairs of primers were used to amplify each gene (see Additional file 1), one specific for unmethylated template and the other specific for methylated template [53]. The 25 mul PCR mixture contained 1 x PCR buffer, 1.0-1.5 mM MgCl2, 20 pmol of each primer, 200 muM dNTP, and 0.625-1.0 U HotStarTaq DNA Polymerase (Qiagen, Valencia, CA). All MSP reactions were run twice, and a third independent MSP round was performed when the results were not concordant. Human placental DNA (Sigma Chemical Co, St. Louis, MO, USA) treated in vitro with SssI methyltransferase (New England Biolabs Inc., Beverly, MA, USA) was used as a positive control for the methylated MSP reaction, whereas DNA from normal lymphocytes was used as a positive control for unmethylated alleles. Water was used as a negative PCR control in both reactions.
###end p 55
###begin title 56
Bisulphite sequencing
###end title 56
###begin p 57
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 205 225 205 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH13, CRABP1, HOXA9</italic>
###xml 231 239 231 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCGB3A1 </italic>
###xml 1017 1019 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
With the use of bisulphite sequencing, original 5-methyl cytosines can be detected as cytosines in the sequence, whereas unmethylated cytosines will be converted to uracils and amplified as thymines [54]. CDH13, CRABP1, HOXA9, and SCGB3A1 (primers are given in Additional file 1) were subjected to direct bisulphite sequencing in the four ovarian carcinoma cell lines. The fragments were amplified with HotStarTaq DNA Polymerase, and excess primer and nucleotides were removed by ExoSAP-IT treatment following the manufacturer's protocol (GE Healthcare, USB Corporation, Ohio, USA). The purified products were subsequently sequenced using the dGTP BigDye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems, Foster City, CA, USA) in an ABI Prism 3730 Sequencer (Applied Biosystems). The approximate ratio of methyl cytosine present in each CpG site was calculated by dividing the peak height of the cytosine signal with the sum of the cytosine and thymine peak height signals, as previously described [55]. CpG sites with ratios from 0-0.2 were classified as unmethylated, ratios from 0.21 - 0.80 were classified as partially methylated, and ratios from 0.81 - 1.0 were classified as methylated.
###end p 57
###begin title 58
Microsatellite instability (MSI)
###end title 58
###begin p 59
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 574 577 574 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e</italic>
###xml 527 534 <span type="species:ncbi:9606">patient</span>
MSI status was determined in all samples using the consensus panel of five microsatellite markers (BAT25, BAT26, D2S123, D5S346, and D17S250) [56] (see Additional file 1). A tumour was considered to be MSI-high if two or more of the five markers exhibited novel alleles compared to normal DNA, MSI-low if only one marker deviated from the normal pattern, and microsatellite stable (MSS) if none of the tumour genotypes showed an aberrant pattern. Control DNA corresponding to the individual tumours was not available from this patient series and thus single allele changes, i.e. the presence of two alleles, can reflect the heterozygote constitutional genotype or a homozygote with a novel tumour specific allele. Thus, dinucleotide markers were not scored when such a pattern appeared in the tumours.
###end p 59
###begin p 60
###xml 159 160 158 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Thirty-seven ng DNA template was amplified in pentaplex, in a ten mul reaction volume consisting of 1 x Multiplex PCR Mastermix (containing buffer, 1.5 mM MgCl2, nucleotides, and enzyme; QIAGEN GmbH, Hilden, Germany), 1.2 pmol BAT25 primers (sense primer labeled with NED in the 5' end), 1.6 pmol BAT26 primers (sense primer labeled with 6-FAM in the 5' end), 1.6 pmol D2S123 primers (sense primer labeled with NED in the 5' end), 1.2 pmol D5S346 primers (sense primer labeled with VIC in the 5' end), 3 pmol D17S250 primers (sense primer labeled with 6-FAM in the 5' end; Applied Biosystems, Foster City, CA, USA). The PCR annealing temperature was 55degreesC and the program included 27 cycles.
###end p 60
###begin p 61
###xml 82 86 71 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
From these PCR products, 0.5 mul was mixed with 0.5 mul GeneScantrade mark 500 LIZ(R) Size Standard (Applied Biosystems) and 9 mul deionized formamide (Kodak Eastman Chemical Company, New Haven, CT, USA). The samples were subsequently denatured and separated by capillary electrophoresis on a 48-capillary 3730 DNA Analyzer (Applied Biosystems, Foster City, CA, USA). Allelic sizes were determined using GeneMapper 3.7 software (Applied Biosystems) and the results were independently scored by two investigators. A second round of analyses confirmed the results.
###end p 61
###begin title 62
Statistical Analysis
###end title 62
###begin p 63
###xml 297 299 297 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 357 359 357 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
All 2 x 2 contingency tables were analyzed using Fisher's exact test. 3 x 2 and 4 x 2 tables were analyzed using Chi square analysis. The potential association between methylation frequencies across all genes analyzed and tumour histology was analyzed by Kruskal-Wallis test (SPSS, version 11.5). P values were derived from two-tailed statistical tests and P <= 0.05 were considered to be statistically significant.
###end p 63
###begin title 64
Competing interests
###end title 64
###begin p 65
The author(s) declare that they have no competing interests.
###end p 65
###begin title 66
Authors' contributions
###end title 66
###begin p 67
All authors have read and approved the final version of the manuscript.
###end p 67
###begin p 68
QW carried out the MSP analyses and the bisulphite sequencing, interpreted the results, performed the statistics, and drafted the manuscript. RAL conceived the study, participated in its design, and contributed with scientific discussion and manuscript preparation. TA ran MSI analyses and contributed to manuscript preparation. IS, CGT, and FM provided clinic data and samples. ZHS and JMN contributed to sample preparation, pathological diagnosis, scientific discussion and manuscript preparation. GEL participated in the design of the study and was responsible for its coordination, provided the epigenetic techniques, interpreted the results independently of author 1, reviewed all statistics, and contributed in the preparation of the manuscript.
###end p 68
###begin title 69
Acknowledgements
###end title 69
###begin p 70
We gratefully acknowledge Merete Hektoen for help with DNA extraction. The Norwegian Cancer Society supported the present study employing GEL as post doc (Grant: 95068, RAL).
###end p 70
###begin article-title 71
The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients
###end article-title 71
###begin article-title 72
Ovarian cancer: epidemiology, biology, and prognostic factors
###end article-title 72
###begin article-title 73
Cancer in Norway 2005
###end article-title 73
###begin article-title 74
Cytosine methylation and the fate of CpG dinucleotides in vertebrate genomes
###end article-title 74
###begin article-title 75
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future
###end article-title 75
###begin article-title 76
The history of cancer epigenetics
###end article-title 76
###begin article-title 77
###xml 41 46 <span type="species:ncbi:9606">human</span>
Comprehensive analysis of CpG islands in human chromosomes 21 and 22
###end article-title 77
###begin article-title 78
Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer
###end article-title 78
###begin article-title 79
###xml 126 131 <span type="species:ncbi:9606">human</span>
Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer
###end article-title 79
###begin article-title 80
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
###end article-title 80
###begin article-title 81
Relevance of DNA methylation in the management of cancer
###end article-title 81
###begin article-title 82
Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer
###end article-title 82
###begin article-title 83
Methylation of serum DNA is an independent prognostic marker in colorectal cancer
###end article-title 83
###begin article-title 84
Control of vascular cell differentiation by homeobox transcription factors
###end article-title 84
###begin article-title 85
###xml 70 75 <span type="species:ncbi:10090">mouse</span>
Methylation of HoxA5 and HoxB5 and its relevance to expression during mouse development
###end article-title 85
###begin article-title 86
Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay
###end article-title 86
###begin article-title 87
Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract
###end article-title 87
###begin article-title 88
Aging, cancer and nutrition: the DNA methylation connection
###end article-title 88
###begin article-title 89
Age- and disease-related methylation of multiple genes in nonneoplastic duodenum and in duodenal juice
###end article-title 89
###begin article-title 90
###xml 68 73 <span type="species:ncbi:10090">mouse</span>
###xml 78 83 <span type="species:ncbi:9606">human</span>
Secretoglobins SCGB3A1 and SCGB3A2 define secretory cell subsets in mouse and human airways
###end article-title 90
###begin article-title 91
HIN-1, an inhibitor of cell growth, invasion, and AKT activation
###end article-title 91
###begin article-title 92
###xml 77 82 <span type="species:ncbi:9606">human</span>
Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies
###end article-title 92
###begin article-title 93
Novel epigenetically deregulated genes in testicular cancer include homeobox genes and SCGB3A1 (HIN-1)
###end article-title 93
###begin article-title 94
ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis
###end article-title 94
###begin article-title 95
###xml 96 101 <span type="species:ncbi:9606">human</span>
Assignment of the genes for cellular retinoic acid binding protein 1 (CRABP1) and 2 (CRABP2) to human chromosome band 15q24 and 1q21.3, respectively, by in situ hybridization
###end article-title 95
###begin article-title 96
ADAMTS-1 is involved in normal follicular development, ovulatory process and organization of the medullary vascular network in the ovary
###end article-title 96
###begin article-title 97
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression
###end article-title 97
###begin article-title 98
###xml 170 175 <span type="species:ncbi:9606">human</span>
Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers
###end article-title 98
###begin article-title 99
###xml 88 93 <span type="species:ncbi:9606">women</span>
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women
###end article-title 99
###begin article-title 100
Promoter hypermethylation profile of ovarian epithelial neoplasms
###end article-title 100
###begin article-title 101
Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer
###end article-title 101
###begin article-title 102
Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours
###end article-title 102
###begin article-title 103
Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis
###end article-title 103
###begin article-title 104
###xml 114 119 <span type="species:ncbi:9606">human</span>
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
###end article-title 104
###begin article-title 105
Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours
###end article-title 105
###begin article-title 106
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies
###end article-title 106
###begin article-title 107
CpG island methylation of DNA damage response genes in advanced ovarian cancer
###end article-title 107
###begin article-title 108
Differences in p16 gene methylation and expression in benign and malignant ovarian tumors
###end article-title 108
###begin article-title 109
Microsatellite instability in gastrointestinal tract cancers: a brief update
###end article-title 109
###begin article-title 110
Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors
###end article-title 110
###begin article-title 111
CpG island methylator phenotype in colorectal cancer
###end article-title 111
###begin article-title 112
CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies
###end article-title 112
###begin article-title 113
Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma
###end article-title 113
###begin article-title 114
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer
###end article-title 114
###begin article-title 115
Prognostic factors for survival of epithelial ovarian cancer
###end article-title 115
###begin article-title 116
Ovarian carcinoma diagnosis
###end article-title 116
###begin article-title 117
Development of an ovarian cancer symptom index: possibilities for earlier detection
###end article-title 117
###begin article-title 118
Cancer epigenetics
###end article-title 118
###begin article-title 119
###xml 114 122 <span type="species:ncbi:9606">patients</span>
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients
###end article-title 119
###begin article-title 120
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool
###end article-title 120
###begin article-title 121
Methylation profile in benign, borderline and malignant ovarian tumors
###end article-title 121
###begin article-title 122
Bisulfite genomic sequencing: systematic investigation of critical experimental parameters
###end article-title 122
###begin article-title 123
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands
###end article-title 123
###begin article-title 124
High sensitivity mapping of methylated cytosines
###end article-title 124
###begin article-title 125
Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia
###end article-title 125
###begin article-title 126
A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer
###end article-title 126

